Subthreshold micropulse yellow (577nm) laser versus intravitreal Ranibizumab in treatment of center involving diabetic macular oedema

Autor:	Esraa Abdelhakeem Diab, Alaa Fathy Mahmoud, Mohamed Abd el-hakim Zaki, Ahmed Abdel-aleem Mohmaed, Mohamed Hanafy Abdel-aziz
Rok vydání:	2021
Předmět:	medicine.medical_specialty Visual acuity genetic structures Subthreshold conduction business.industry Diabetic macular edema General Medicine Diabetic macular oedema Ophthalmology medicine Intravitreal ranibizumab medicine.symptom Ranibizumab business medicine.drug
Zdroj:	QJM: An International Journal of Medicine. 114
ISSN:	1460-2393 1460-2725
DOI:	10.1093/qjmed/hcab109.010
Popis:	Purpose To evaluate the effectiveness of subthreshold micropulse laser as compared to intravitreal injection of ranibizumab in treatment of center involving diabetic macular oedema. Methods A total of 76 eyes of 62 patients with center involving diabetic macular oedema were divided into two groups. Group A received intravitreal injection of ranibizumab while group B received subthreshold micropulse laser with rescue intravitreal injection of ranibizumab. The change from baseline in best correscted visual acuity and central subfield thickness were compared at 3, 6, 9 and 12 months follow-up. Any adverse effects were recorded. Results Group A (n = 34 eyes) experienced a statistically significant improvement in best corrected visual acuity (from 0.32±0.16 Log MAR at baseline to 0.21±0.14 Log MAR at 12 months) (P value =0.006), with a statistically significant reduction in central subfield ghickness (from 352.06±34.34µm to 289.47±58.88 µm) (P value=0.001). Group B (n = 42 eyes), also experienced a statistically significant improvement in best corrected visual acuity (from 0.34±0.22 Log MAR at baseline to 0.13±0.31 Log MAR at 12 months) (P value=0.001), with a statistically significant reduction in central subfield thickness (from 300±47.34µm to 253.12±39.60 µm at 12 months) (P value= 0.009). The mean difference in best corrected visual acuity between the group B and group A was -0.08 Log MAR with a 95% CI ranging from -0.197 to 0.037, which supports the claim of non-inferiority between the two treatment regimens. No adverse effects from subthreshold micropulse laser were recorded in both groups. Conclusion subthreshold micropulse laser with rescue intravitreal injection of ranibizumab was non inferior to intravitreal injection of ranibizumab in treatment of center involving diabetic macular oedema as regards the mean change in best corrected visual acuity.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::69efc7727e6d43bc0027696f32dac42d https://doi.org/10.1093/qjmed/hcab109.010 Zobrazit plný text záznamu